The Trump administration just slapped a 100% tariff on imported brand-name drugs, the most aggressive trade action the pharmaceutical industry has ever seen. Some major drugmakers already cut deals to dodge it. The rest are scrambling.
Imagine walking into a pharmacy and learning that the price of your medication just doubled. Not because the drug changed. Not because a new study proved it works better. Because of a tariff.
That's the reality the Trump administration just set in motion. In late September 2025, the White House announced a 100% tariff on imported brand-name drugs and their ingredients. If a patented medicine is made overseas and shipped into the U.S., it now faces a duty that effectively doubles its landed cost. The move is the most aggressive trade action ever taken against the pharmaceutical industry, and it's already reshaping how the world's biggest drugmakers think about where they build, what they charge, and who they negotiate with.
The Tariff That Wants to Be a Negotiation
The headline number is 100%, but this policy is really a giant game of Let's Make a Deal. The administration built in a tiered system of exemptions and lower rates designed to reward companies that play ball.
Here's how the tiers shake out. If a company gets an onshoring plan approved by the Commerce Secretary (meaning it commits to building or expanding U.S. manufacturing), the tariff drops to 20%. Products from Japan, the EU, South Korea, and Switzerland generally face a 15% rate instead of the full 100%, though specific trade agreements may provide lower rates for certain product categories — for example, Japan's trade agreement exempted generic pharmaceuticals entirely. The United Kingdom gets its own special rate tied to a broader trade arrangement, with reports suggesting it could eventually fall to zero. And companies that both move production stateside and agree to Most-Favored-Nation pricing (essentially charging Americans no more than they charge other wealthy countries) can qualify for a 0% tariff.
Generic drugs, biosimilars, and U.S.-made products? All excluded. For now.
The effective dates are staggered, too: July 31, 2026 for companies listed in the proclamation's Annex III, and for everyone else. The message is clear: you've got a window. Use it or pay up.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
September 29, 2026
Who's Already Cut a Deal (and Who Hasn't)
Some of pharma's biggest names moved fast. Pfizer, Merck, Bristol Myers Squibb, and AstraZeneca have reportedly avoided the full tariff by negotiating agreements with the administration. The specifics of those deals aren't fully public, but the pattern is consistent with the administration's broader strategy: lower your U.S. prices, commit to domestic production, and we'll lower your tariff.
The companies that haven't reached a deal? They're the ones staring down the barrel of a 100% duty. The complete list isn't public, but any brand-name drugmaker that imports patented products without an exemption or onshoring plan is fully exposed. For multinational pharma companies that manufacture heavily in Ireland, Singapore, or Puerto Rico (which, despite being a U.S. territory, has complicated trade treatment for some products), this is a five-alarm fire.
16 Months of Escalation
This tariff didn't come out of nowhere. It's the crescendo of a policy drumbeat that started more than a year ago.
In April 2025, the administration signed an executive order titled "Lowering Drug Prices by Once Again Putting Americans First," laying out a broad agenda to reduce prescription costs. A month later, in May 2025, another order followed, directing HHS to pursue Most-Favored-Nation pricing.
By mid-2025, the White House was sending letters directly to major drugmakers, pushing for price cuts. By early 2026, the administration launched TrumpRx.gov, a platform for discounted cash-pay drug access, and called on Congress to codify MFN savings into law.
When legislation stalled, the tariff hammer came out. Think of it like a landlord who asks nicely for the rent three times, then shows up with an eviction notice.
Can You Actually Build a Pill Factory That Fast?
The administration's pitch is straightforward: make drugs in America, and you won't pay the tariff. Simple in theory. Brutally hard in practice.
Pharmaceutical manufacturing isn't like setting up a new fulfillment center for an e-commerce company. Building a drug plant takes years of construction, regulatory validation, and specialized workforce training. The FDA doesn't just rubber-stamp a new facility; it inspects, audits, and re-inspects. Even with the 2025 executive order pushing FDA to speed things up, experts say full-scale reshoring of complex drug manufacturing is not feasible in the short term.
What is feasible? Marginal steps. Companies can shift packaging, fill-finish operations (the final step where drugs get put into vials or syringes), and some incremental capacity expansions to the U.S. relatively quickly. But the active pharmaceutical ingredients, the actual molecules that make a drug work, often depend on global supply chains that stretch back to facilities in India, China, and Europe. Those upstream dependencies don't disappear because of a tariff.
The most likely near-term outcome isn't wholesale relocation; it's reconfiguration. More U.S. contracting for high-value finishing steps, while the raw ingredients and intermediates still flow from overseas. The tariff changes the math at the margins, but it doesn't rewrite the physics of building a sterile manufacturing facility.
The Real Question: Who Pays?
Tariffs are paid by importers, not by foreign governments. That's Econ 101. So when a 100% duty lands on a brand-name drug, the importing company eats the cost, passes it along to insurers, or raises the list price for patients. In practice, it's usually some combination of all three.
For the big companies that already struck deals, the impact may be muted. They negotiated lower tariff rates in exchange for pricing concessions and manufacturing commitments. But for companies that didn't (or couldn't) cut a deal, the math gets ugly fast. A drug that costs $10,000 per course of treatment to import now effectively costs $20,000 before it even reaches a pharmacy shelf.
Analysts and trade groups have been sounding alarms. PhRMA, the brand-name drug industry's main lobbying group, has argued that tariffs on branded medicines could undermine U.S. drug innovation and supply chains. BIO, the biotech trade group, has echoed similar concerns, warning that tariffs on innovative medicines raise manufacturing costs and complicate investment decisions.
The downstream effects on insurance premiums are harder to quantify, but the direction is clear: upward. If drug acquisition costs rise, insurers face higher pharmacy spending, and those costs eventually land in your monthly premium. Nobody has put a precise number on the premium impact yet, but the pressure is real.
The Generic Shoe That's Waiting to Drop
Remember how generics are excluded from this tariff? Don't get too comfortable. In a separate announcement in July 2026, the administration previewed a plan to impose tariffs on generic drugs starting in August 2028, ramping from 100% to 200% by 2029.
That's a much scarier prospect in some ways. Generic medications account for roughly 90% of U.S. prescriptions. They operate on razor-thin margins, which means manufacturers have almost no room to absorb new costs. Industry voices like John Murphy of the Association for Accessible Medicines have called for "dialogue" with the administration, warning that tariffs on generics could make lower-cost medicines harder to access.
If the brand-name tariff is a negotiating lever, the generic tariff proposal is a ticking clock. The administration is essentially telling the entire pharmaceutical supply chain: start building in America now, because in two years, everyone pays.
What This Means for Biotech
Small and mid-cap biotech companies are in a particularly awkward spot. Most don't manufacture their own drugs. They contract with CDMOs (contract development and manufacturing organizations) that operate globally. If your drug is made at a facility in Ireland or Switzerland and you don't have the scale or leverage to negotiate your own tariff exemption, you're suddenly looking at a cost structure that could make your product uneconomic.
For companies still in clinical development, the calculus shifts too. Planning where to manufacture a drug that might launch in 2028 or 2029 now requires factoring in tariff scenarios that didn't exist a year ago. The cost of building U.S. capacity into your manufacturing strategy just went from "nice to have" to "existential."
The broader implication is that this tariff accelerates a trend that was already underway: the slow, expensive, politically driven push to bring pharmaceutical manufacturing back to the United States. Whether that's good policy or economic theater depends on whom you ask. But the 100% number on the proclamation isn't a bluff. It's a price tag, and someone is going to pay it.
5 min read
The Drug That Treats Narcolepsy by Actually Fixing What's Broken
Takeda just got FDA approval for the first drug that actually restores the broken brain signal behind narcolepsy type 1, and it took a spectacular failure and 26 years of science to get here. The orexin era of sleep medicine has officially arrived.
